GCL
DMAAR

Glazer Capital LLC’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Glazer Capital LLC’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18K Sell
297,475
-239,377
-45% -$25.4K ﹤0.01% 439
2025
Q4 		$101K Sell
536,852
-51,448
-9% -$9.98K ﹤0.01% 281
2025
Q3 		$128K Sell
588,300
-711,700
-55% -$132K ﹤0.01% 224
2025
Q2 		$156K Hold
1,300,000
– – 0.01% 171
2025
Q1 		$169K Buy
+1,300,000
New +$183K 0.01% 135

Other funds holding DMAAR

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Glazer Capital LLC's DMAAR Position: Q1 2026 in Review

Glazer Capital LLC reduced its Drugs Made In America Acquisition Corp Rights (DMAAR) stake by 45% in Q1 2026, selling an estimated $25.4K and leaving 297,475 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #439.

Glazer Capital LLC first reported a position in DMAAR in Q1 2025 and has held it in 5 quarters since. The position peaked at $169K in Q1 2025. 35 funds tracked by Wall St. Rank hold DMAAR as of Q1 2026.

  • Glazer Capital LLC held 297,475 shares of Drugs Made In America Acquisition Corp Rights worth $18K as of Q1 2026.
  • Glazer Capital LLC sold 239,377 Drugs Made In America Acquisition Corp Rights shares in Q1 2026, an estimated $25.4K.
  • Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of Glazer Capital LLC's portfolio in Q1 2026, its #439 holding.
  • Glazer Capital LLC first reported a position in Drugs Made In America Acquisition Corp Rights in Q1 2025 and has held it in 5 quarters since.
  • Glazer Capital LLC's Drugs Made In America Acquisition Corp Rights position peaked at $169K in Q1 2025.
  • 35 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q1 2026.

Based on Glazer Capital LLC's 13F filing for Q1 2026, filed 14 May 2026.